FluoSphera SA

Predicting clinical drug response with multi-tissue systems.

FluoSphera has developed human multi-tissue systems that accurately replicate and analyze how a drug interacts with multiple organs. FluoSphera's technology addresses a critical gap in preclinical drug development by enabling the selection of the best candidate drugs based on their predicted systemic response in humans — ultimately determining clinical success for patients. By accurately predicting drug safety and efficacy, this approach reduces the likelihood of failure during clinical development, improves patient access to effective treatments, and minimizes the need for animal testing.

Only registered users have access to funding information.
Please log in or register to continue. Registration is free.

No milestones

No Jobs

No videos and documents

TOP 100 Swiss Startup Award

The TOP 100 Swiss Startup Ranking features the 100 most promising startups that are not older than five years and are selected by a jury of early-stage investors.

Website

Venture Kick

Venture Kick supports potential entrepreneurs with start capital up to CHF 150'000 as well as hands-on execution support and access to a nationwide network of investors and experts in the startup field. Multiple times per year, 8 selected projects get the opportunity to present their business ideas in front of a panel. The 5 most promising projects enter the support process. After 9 months at the latest, the startups incorporate and enter the market. Since 2007, Venture Kick has invested over CHF 58 million in over 1111 projects.

Website

FluoSphera SA

Predicting clinical drug response with multi-tissue systems.

Headquarter:
Plan-les-Ouates

Foundation Date:
November 2021

Technology:

  • Biotech

Sectors:

  • Antibodies
  • Biotech
  • Cancer
  • Drug development platforms
  • Drug discovery
  • Research and development
  • Services for companies
  • Organ and Tissues
  • Screening
  • Small molecule drugs

Support received

  • Support venturekick
  • Support TOP 100